Cargando…
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
AIMS: Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is an orally administered no...
Autores principales: | Tardif, Jean‐Claude, Rouleau, Jean, Chertow, Glenn M., Al‐Shurbaji, Ayman, Lisovskaja, Vera, Gustavson, Stephanie, Zhao, Yanli, Bouabdallaoui, Nadia, Desai, Akshay S., Chernyavskiy, Alexander, Evsina, Maria, Merkely, Béla, McMurray, John J.V., Pfeffer, Marc A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053160/ https://www.ncbi.nlm.nih.gov/pubmed/36564955 http://dx.doi.org/10.1002/ehf2.14268 |
Ejemplares similares
-
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE
por: Fishbane, Steven, et al.
Publicado: (2022) -
Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2022) -
A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin
por: Någård, Mats, et al.
Publicado: (2022) -
Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
por: Fishbane, Steven, et al.
Publicado: (2023) -
Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)